// App-Quantinova.ai

3933 : Phase 2 Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia

Researchers

Presenter

  • Suzanne Fanning

Principal Investigators

  • Joseph Stephenson

  • Lawrence Afrin

  • Tricia Bentz

  • Shanta Salzer

  • Rachel Whirley

  • Carlyn Sander

  • Robert K Stuart

Medical Centers

  • Greenville Memorial University Hospital,

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Hepatitis B

  • Neutropenia

  • Solid malignancies

Biomarkers

  • Alanine transaminase

  • Aspartate aminotransferase

  • Circulating tumor cells

  • Zeta-chain-associated protein kinase 70

Drug/Treatment

  • HA20

  • Glucocorticoid

  • Lenalidomide

  • Trimethoprim

  • ofatumumab Intravenous

  • Rituximab

  • Acyclovir

  • ZAP70

Outcome

  • N/A

Study Design

  • pharmacodynamics

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved